Clinical trials · New York, NY
Colorectal Cancer Screening clinical trials in New York
We’re tracking 49 recruiting colorectal cancer screening studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT04751435Recruiting
Genetic testing education for cancer patients of diverse backgrounds
This study tests new educational materials about genetic testing for cancer patients. It aims to find the best ways to explain genetic testing to people from different backgrounds, especially Black, Latino, and non-Latino non-Black communities.
New York, New YorkAges 18 years+ - NCT06184594Enrolling by invitation
Using eNav Toolkit to boost colon cancer screening
This trial tests a computer program (eNav Toolkit) to help people decide about colon cancer screening. If you are between 45 and 75 and due for screening, this study may help you make an informed choice.
New York, New YorkAges 45–75 - NCT06228209Recruiting
Palliative care for advanced heart failure or cancer
This study tests whether adding a palliative care specialist to your regular care team can improve your quality of life if you have advanced heart failure or advanced lung or certain gastrointestinal cancers. It is for people who have been in the hospital recently and live in Manhattan.
New York, New YorkAges 18 years+ - NCT06880055RecruitingTeam says not enrolling
Shield blood test for colorectal cancer screening
This study is testing the Shield blood test for people at average risk of colorectal cancer. It looks at how well the test works for screening, so you can learn about your risk with a simple blood draw.
New York, New YorkAges 45–81 - NCT05253651RecruitingPhase 3
Tucatinib plus trastuzumab with chemo for HER2+ metastatic colon cancer
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
New York, New YorkAges 18 years+ - NCT06324357RecruitingPhase 1/Phase 2
Zongertinib for HER2-positive cancers that have spread
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
New York, New YorkAges 18 years+ - NCT06992258RecruitingPhase 2
Comparing two drug combinations for advanced colorectal cancer
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
New York, New YorkAges 18 years+ - NCT07535112RecruitingPhase 1
Testing BAY 3771249 for Advanced Colorectal Cancer With KRAS Mutation
This early-stage study tests a new drug called BAY 3771249 in people with advanced colorectal cancer that has a specific genetic change (KRAS G12D mutation). Researchers want to learn if it's safe and whether it helps shrink tumors.
New York, New YorkAges 18 years+ - NCT07033026RecruitingPhase 2
Study of NGM120 for weight loss in colorectal cancer
This study tests an experimental drug called NGM120 for people with colorectal cancer who are losing weight (a condition called cancer cachexia). It is a placebo-controlled trial, meaning some participants will receive the drug and some will receive a placebo, to see if the drug helps stop or reverse this weight loss.
New York, New YorkAges 18 years+ - NCT07227636RecruitingPhase 2
Immunotherapy for ctDNA-positive colorectal cancer after surgery
This trial tests two immunotherapy drugs, botensilimab and balstilimab, for people with colorectal cancer who have had surgery and chemotherapy but still have detectable cancer DNA in their blood. The goal is to see if these drugs can help clear the remaining cancer cells.
New York, New YorkAges 18 years+ - NCT07094204RecruitingPhase 1
A study of ASP5834 for adults with solid tumors and KRAS mutations
This trial is testing a new drug called ASP5834 for people with advanced solid tumors that have a specific change in the KRAS gene. The study will find the best dose and see if it helps shrink tumors.
New York, New YorkAges 18 years+ - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
New York, New YorkAges 18 years+ - NCT06562543RecruitingPhase 4
Fruquintinib for advanced colorectal cancer in minority populations
This trial tests a medication called fruquintinib (an oral pill) for people with advanced colorectal cancer that has not responded to prior treatments. It is specifically looking for participants who identify as Black or African American and/or Hispanic or Latino to help understand how the drug works in these groups.
New York, New YorkAges 18 years+ - NCT05742178Recruiting
Cancer screening outreach and help in select NYC neighborhoods
This study tests an outreach program that helps people who may be behind on cancer screenings get connected to the right care. It mainly aims to reduce missed screenings in specific Brooklyn and Bronx communities.
New York, New YorkAges 21–75 - NCT07361614Recruiting
Colorectal cancer education program
This study tests a program to help people learn about colorectal cancer screening. If you are 45 to 75 and due for screening, you may be able to join.
New York, New YorkAges 45–75 - NCT07262619RecruitingPhase 1/Phase 2
Study of EIK1005 for advanced solid tumors
This study tests an experimental drug called EIK1005, either alone or combined with another drug (pembrolizumab), for people with advanced solid tumors, especially those with MSI-H or dMMR cancers (tumors that have trouble repairing their DNA). The goal is to see if it can shrink tumors or slow cancer growth.
New York, New YorkAges 18 years+ - NCT06997497RecruitingPhase 3
Study of Calderasib with other drugs for colorectal cancer
This trial tests a new drug called Calderasib combined with targeted therapy or chemotherapy for people with advanced colorectal cancer that has a specific genetic change (KRAS G12C mutation). It may be an option for those who have not had prior treatment for advanced disease.
New York, New YorkAges 18 years+ - NCT04589468Recruiting
Exercise for cancer survivors at high risk
This study tests whether a structured exercise program can help prevent cancer from coming back in people who have been treated for certain solid tumors (colorectal, ovarian, lung, or breast cancer). If you've completed surgery and adjuvant therapy within the past 2 years and are currently not exercising much, you may be eligible. Participation involves following an exercise plan and regular check-ins.
New York, New YorkAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
New York, New YorkAges 18 years+ - NCT06750094RecruitingPhase 3
Study of amivantamab plus FOLFIRI in colorectal cancer
This trial tests adding amivantamab to standard FOLFIRI chemotherapy for people with certain types of colorectal cancer that have already been treated once. It aims to see if this combination works better than another common treatment (cetuximab or bevacizumab plus FOLFIRI).
New York, New YorkAges 18 years+ - NCT07114601RecruitingPhase 1
Study of LY4257496 for people with GRPR-positive solid tumors
This trial tests a new drug, LY4257496, in people with certain types of cancer that have a protein called GRPR on their cells. The study aims to see if the drug can help shrink tumors or slow the cancer's growth.
New York, New YorkAges 18 years+ - NCT06529523RecruitingPhase 2
Testing tislelizumab for dMMR colorectal cancer
This trial tests the immunotherapy drug tislelizumab for people with a specific type of colorectal or rectal cancer called dMMR. It aims to see if this treatment can shrink tumors or improve outcomes in patients who haven't had many other treatments.
New York, New YorkAges 18 years+ - NCT06096688Recruiting
Finding new ways to lower colorectal and endometrial cancer risk
This study looks for new ways to lower the risk of colorectal and endometrial cancers. It collects tissue and information from people who are getting certain procedures or treatments at Weill Cornell Medicine.
New York, New YorkAges 18 years+ - NCT00843375Recruiting
Testing stool samples to find early colon cancer and polyps
This study checks stool samples to see how well stool tests can detect early colon cancer and precancerous growths called adenomas. If you qualify, you’ll collect stool samples for a lab test (FIT) and sometimes this helps sort who should get follow-up testing.
New York, New YorkAges 18 years+
Hear when a new Colorectal Cancer Screening trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Where these studies are running near New York
Institutions with a site for the recruiting colorectal cancer screening studies listed above.
- Memorial Sloan Kettering Cancer Center · 11 studies
- NYU Langone Health · 6 studies
- Memorial Sloan Kettering Bergen · 3 studies
- Memorial Sloan Kettering Monmouth · 3 studies
- Memorial Sloan Kettering Nassau · 3 studies
- Albert Einstein College of Medicine · 2 studies
- Icahn School of Medicine at Mount Sinai · 2 studies
- Memorial Sloan Kettering Basking Ridge · 2 studies
What taking part in a colorectal cancer screening study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there colorectal cancer screening clinical trials near New York?
- Yes. We're currently tracking 49 recruiting colorectal cancer screening studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a colorectal cancer screening study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a colorectal cancer screening trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New colorectal cancer screening studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.